Overview

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Status:
RECRUITING

Trial end date:
2033-04-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease (MRD) in the bone marrow with elranatamab and daratumumab employed as post-induction consolidation and maintenance treatment (Arm A) versus autologous stem cell transplant (ASCT) followed by lenalidomide and daratumumab treatment (Arm B).

Phase:

PHASE2

Details

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborators:

coMMit, Myeloma Trials, Innovated
Pfizer

Treatments:

daratumumab
Lenalidomide